From: The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage
Variables
Value
P value
Group B
Ratio CTGF/log10(VEGF) before IVR
0.399 ± 0.141
0.051
Ratio CTGF/log10(VEGF) after IVR
0.724 ± 0.624
Group C
0.553 ± 0.284
0.046
0.803 ± 0.387